GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Selling, General, & Admin. Expense

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Selling, General, & Admin. Expense : $0.27 Mil (TTM As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Eucrates Biomedical Acquisition's selling, general, & admin. expense for the three months ended in Dec. 2022 was $0.00 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2022 was $0.27 Mil.


Eucrates Biomedical Acquisition Selling, General, & Admin. Expense Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Selling, General, & Admin. Expense Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Selling, General, & Admin. Expense
- 0.74 -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.13 0.14 - -

Competitive Comparison of Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense falls into.



Eucrates Biomedical Acquisition Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eucrates Biomedical Acquisition  (NAS:EUCRU) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Eucrates Biomedical Acquisition Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines